linjc16/ctgov huggingface dataset:
Cold Stress Stimulate the Browing of Subcutaneous White Adipose in Healthy Adults

Study Overview
=================
Brief Summary
-----------------
Adipose tissues, which include white adipose tissue (WAT) and brown adipose tissue (BAT), play an essential role in regulating whole-body energy homeostasis. Recent studies also reveal the presence of a subset of cells in WAT that could be induced by environmental or hormonal factors to become ''brown-like'' cells, and this ''beigeing'' process has been suggested to have strong antiobesity and antidiabetic benefits. More recently, same studies showed that cold stress stimulate the browning of subcutaneous white adipose. However, to the investigators knowledge, there are no direct data that clearly show that cold stress can promote the browning of subcutaneous white adipose.

Detailed Description
-----------------
Individuals have cold exposure at 15C for 2 hr everyday for one week.Biopsy for subcutaneous white adipose was performed before and after one week cold exposure programme under local anesthesia. Measure the brown fat characteristics of biopsy samples. The expression levels of uncoupling protein-1 (UCP-1), peroxisome proliferator-activated receptor (PPAR)-r, peroxisome proliferator-activated receptor r coactivator 1 a (PGC1a) , growth factor receptor binding protein-10 (Grb10), PR domain containing 16 (PRDM16) will be determined before and after cold stress programme from the biopsy samples. In addition, a combination of PET and computed tomography (CT) - with the glucose analogue 18F-fluorodeoxyglucose (18F-FDG) as a tracer will be performed for brown adipose tissue before and after cold stress programme.

Official Title
-----------------
Cold Stress Stimulate the Browing of Subcutaneous White Adipose in Healthy Adults

Conditions
-----------------
Obesity, Type 2 Diabetes

Intervention / Treatment
-----------------
* Other: cold stress


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy men 18-60 years old BMI 20-28 kg/m2 Exclusion Criteria: BMI < 20 kg/m2 BMI > 28 KG/M2 Female

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: healthy adults<br> | Other: cold stress<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| browning of subcutaneous white adipose | Brown fat characteristics of biopsy samples will be assessed by determining the expression levels of UCP1, PGC1a, PRDM16 and Grb10. | 4 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Brown adipose tissue, Subcutaneous white adipose tissue, White adipose tissue
Study of 3 Doses of ARD-0403 in Testosterone Deficient Men

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine which dose, if any, results in testosterone levels within the normal range for men.

Official Title
-----------------
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Multi-Centre Study of the Pharmacokinetics and Tolerability of 3 Different Doses of ARD-0403 in Testosterone Deficient Men

Conditions
-----------------
Hypogonadism

Intervention / Treatment
-----------------
* Drug: ARD-0403


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Testosterone deficiency Normal BMI Exclusion Criteria: Previous treatment with testosterone replacement therapy within 4 weeks Moderate-severe benign prostatic hypertrophy, or prostatic cancer Haematocrit >50%

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: ARD-0403|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pharmacokinetic |  |  |
Shrunken Pore Syndrome: a Retrospective, Single Center, Cohort Study

Study Overview
=================
Brief Summary
-----------------
To study the impact a difference in renal clearance of small and large molecules has on long-term survival.

Detailed Description
-----------------
Renal dysfunction is considered a major risk factor in cardiac surgery. Renal function has earlier been estimated by creatinine and more recently by cystatin C, both of which are analysed in a blood sample. New evidence seems to suggest that if the ratio between estimated renal function from cystatin C and creatinine is below 60% the patient has a higher rate of mortality irrespective of renal function. This syndrome is named Shrunken Pore Syndrome. We study patients whom have undergone elective cardiac surgery at our institution and on whom we before the surgery has collected blood samples. They are all included in our in house patient registry and qulaity database and afterwards we match this data to our national tax registry to get data on mortality. Our aim is to evaluate whether Shrunken Pore Syndrome influence mortality following elective cardiac surgery.

Official Title
-----------------
Shrunken Pore Syndrome's Effect on Mortality in Elective Cardiac Surgery

Conditions
-----------------
Kidney Diseases

Intervention / Treatment
-----------------
* Diagnostic Test: Shrunken Pore Syndrome


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Elective CABG and/or sAVR at the department of Cardiothoracic Surgery, Skåne University Hospital in Lund, Sweden between 1 January 2010 and 31 December 2015. Exclusion Criteria: Emergency operation Redo operation Preoperatively missing cystatin C or creatinine

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Shrunken Pore Syndrome|eGFR Cystatin C ≤ 60% of eGFR Creatinine|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality during follow up | All cause mortality at follow up | 1 January 2010 - 1 January 2019 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
CKD, Creatinine, Cystatin C, Cardiac surgery, GFR
Cesarean-scar Thickness and Closure Technique

Study Overview
=================
Brief Summary
-----------------
The aim of this trial is the surgical method in cesarean deliveries, especially the uterotomy closure technique.

Detailed Description
-----------------
The aim of this prospective, randomized controlled trial was to longitudinally evaluate uterine-scar remodeling via transvaginal ultrasound after single- or double-layer uterine closure six weeks and at least six months after Cesarean delivery. The women were included at their booking visit for an elective CD or during labor before an nonemergent CD. They were randomly assigned for three different uterotomy suture techniques: The uterus was closed with a continuous single layer locked stitch or continuous single unlocked layer or double layer. Six weeks and between six and twenty-four month after their cesarean delivery the women were examined by transvaginal ultrasound with an empty maternal bladder, in a supine decubitus position using a GE E8 system equipped with a 5-9 MHz transducer (GE Healthcare, Milwaukee, WI). The measurement of the uterine scar thickness was performed perpendicular to the uterine wall and was defined as shortest visible distance between the decidua and the delineation of the endometrium at the level of the cesarean scar.

Official Title
-----------------
Longitudinal Transvaginal Ultrasound Evaluation of Cesarean-scar Thickness in the First Two Years After Single- or Double-layer Uterotomy Closure: a Prospective Randomized Study

Conditions
-----------------
Uterine Scar Remodeling

Intervention / Treatment
-----------------
* Procedure: cesarean section technique


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Elective cesarean section Cesarean section during labor Exclusion Criteria: Emergency cesarean section Declined to participate
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Single-layer unlocked closure<br> | Procedure: cesarean section technique<br>* Comparing three different types of suturing the uterus at Cesarea section<br>|
| Active Comparator: Single-layer locked closure<br> | Procedure: cesarean section technique<br>* Comparing three different types of suturing the uterus at Cesarea section<br>|
| Active Comparator: Double-layer closure<br>The first layer was continuous and unlocked and a second, continuous non-locking imbricating layer was applied over the first suture. | Procedure: cesarean section technique<br>* Comparing three different types of suturing the uterus at Cesarea section<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| cesarean scar-thickness |  | 24 months |
Effects of Increased Tidal Volume on Internal Jugular Vein Cross-sectional Area

Study Overview
=================
Brief Summary
-----------------
As increasing tidal volume, the cross sectional area and circumference of Internal Jugular Vein (IJV) could increase. And In the previous study, Trendelenburg position can increase size of IJV. So investigators would compare the cross sectional area, circumference of IJV and peak airway pressure in neutral and Trendelenburg position

Official Title
-----------------
Effects of Increased Tidal Volume on Internal Jugular Vein Cross-sectional Area

Conditions
-----------------
General Anesthesia, Surgery

Intervention / Treatment
-----------------
* Other: Tidal Volume


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients who are undergoing general anesthesia Exclusion Criteria: history of IJV cannulation uncontrolled cardiovascular disease severe pulmonary problem cervical spinal impairment

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Neutral<br> | Other: Tidal Volume<br>* observation of IJV circumference and cross sectional area using ultrasonography by changing of tidal volume<br>|
| Active Comparator: Trendelenberg<br> | Other: Tidal Volume<br>* observation of IJV circumference and cross sectional area using ultrasonography by changing of tidal volume<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
any operation that required for general anesthesia
Predicting Medication Response for Autoimmune Disease

Study Overview
=================
Brief Summary
-----------------
Coral is conducting a large study comparing and predicting the relative effectiveness of different medications for autoimmune patients. Patients with Inflammatory Bowel Disease (IBD) who have been diagnosed with either Ulcerative Colitis or Crohn's Disease and are undergoing treatment are eligible to participate. Patients with Rheumatoid Arthritis (RA) and Psoriasis (Ps) will also be enrolled. A novel clinical test will be performed to predict the responsiveness of a particular patient to different immune modulating therapies used in these conditions.

Official Title
-----------------
Predicting Medication Response for Autoimmune Disease

Conditions
-----------------
Ulcerative Colitis, Crohn's Disease, Psoriasis, Rheumatoid Arthritis

Intervention / Treatment
-----------------
* Diagnostic Test: Coral FRS test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Ulcerative Colitis, Crohn's Disease, Rheumatoid Arthritis, Psoriasis diagnosis On or about to begin a treatment for condition above

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Ulcerative Colitis<br> | Diagnostic Test: Coral FRS test<br>* A novel clinical test to predict autoimmune medication response<br>|
| Crohn's Disease<br> | Diagnostic Test: Coral FRS test<br>* A novel clinical test to predict autoimmune medication response<br>|
| Rheumatoid Arthritis<br> | Diagnostic Test: Coral FRS test<br>* A novel clinical test to predict autoimmune medication response<br>|
| Psoriasis<br> | Diagnostic Test: Coral FRS test<br>* A novel clinical test to predict autoimmune medication response<br>|
| Control<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prediction of medication response | AUC measure | retrospective and 6 months prospectively | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prediction of disease severity | R-squared measure of predicting current disease severity measure | at enrollment | 
| Classification of disease | AUC measure at determining the diagnosis/disease of a patient | at enrollment |
Development and Validation of the Patient-completed Caprini Risk Score

Study Overview
=================
Brief Summary
-----------------
The investigators aimed to test the reliability and validity of the Chinese version of patient-completed CRS in hospitalized patients and to evaluate whether this form can be widely used in clinical practice instead of only health care workers' evaluation.

Official Title
-----------------
Patient-Completed Caprini Risk Score for Venous Thromboembolism Risk Assessment Developed and Validated From 1017 Medical and Surgical Patients: a Diagnostic Study

Conditions
-----------------
Venous Thromboembolism

Intervention / Treatment
-----------------
* Diagnostic Test: patient-completed Caprini Risk Score


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients older than 18 years patients with first admission to the medical and surgical units within 24 hours willingness to participate in the study Exclusion Criteria: patients with a diagnosis of PTE or DVT on admission patients with cognitive impairment inability to read or write patients with mental diseases patients with visual impairment refusal to cooperate
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Trained nurse-completed CRS<br> | Diagnostic Test: patient-completed Caprini Risk Score<br>* The participants will be asked to complete patient-completed Caprini Risk Score<br>|
| Patient-completed CRS<br> | Diagnostic Test: patient-completed Caprini Risk Score<br>* The participants will be asked to complete patient-completed Caprini Risk Score<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Question-to-question agreement between patient-completed and nurse-completed CRS | The investigators will use kappa value to compare the question-to-question agreement level between nurse and patient-completed Caprini Risk Score | one year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation and difference between the scores calculated by patient-completed and nurse-completed CRS | The Spearman correlation coefficient was used to measure the correlation and difference between patient-completed and nurse-completed CRS. | one year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Validation, VTE risk, Caprini, Patient-complete
EEG and Auditory Evoked Potentials During Local Anesthesia

Study Overview
=================
Brief Summary
-----------------
The aim of the present study was to investigate the sensitivity of AEP (auditory evoked potentials) to muscular artefacts using sedation and local anesthesia.

Detailed Description
-----------------
Spontaneous or evoked electrical brain activity is increasingly used to monitor general anesthesia. During alertness, surgery and anesthesia the quality of AEP recordings may be reduced by artefacts. This poses the question to what extent AEP are sensitive for muscular artefacts. High frequency artefacts can have its seeds in muscles and in technical instruments in the operating room. Therefore, the study will take place under the terms of laboratory. The present study was designed to measure the influence of muscular artefacts on AEP under propofol sedation with or without local anesthesia in the area of the electrodes. If artefacts influence AEP, which are used to measure anesthesia, it is particularly interesting with regard to clinical application. AEP as a measure of anesthetic depth may not only reflect brain, but also muscular and high frequency activity. Therefore, while using muscle relaxants, the AEP of an awake patient may indicate deep anesthesia, because muscle signals are absent.

Official Title
-----------------
EEG and Auditory Evoked Potentials During Local Anesthesia

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: Propofol
* Drug: Prilocaine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: American Society of Anesthesiologists (ASA) physical status 1-2 Exclusion Criteria: drugs that effect the central nervous system neurological or psychiatric deceases contraindications against use of propofol or local anesthesia

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Propofol|nan|
|Drug: Prilocaine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| differences of AEP during sedation with and without local anaesthesia |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| fraction of high frequency artefacts |  |  | 
| time to LOC |  |  | 
| differences AEP awake with and without local anaesthesia |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
EEG, AEP, Artefacts, Propofol, Local Anaesthesia
Feasibility Study of the JewelPump Version 3

Study Overview
=================
Brief Summary
-----------------
The study will be conducted, in cross-over with a time interval of at least 2 days between 2 treatment periods. Patients will be randomized into 2 groups According to the order of the randomization, patients will bear the JewelPump for 5 days, followed by a period of 5 days of treatment with their usual pumps.

Detailed Description
-----------------
The JewelPump (Debiotech) will be compared to the conventional pumps. Patients will treated with the JewelPump during 5 days, and with their usual pump during 5 other days. The study will be conduct with 15 patients at the following investigation centers : Corbeil Hospital, CHU of Strasbourg, and CHRU of Marseille.

Official Title
-----------------
Feasibility Study of the JewelPump Version 3

Conditions
-----------------
Type 1 Diabetes

Intervention / Treatment
-----------------
* Device: JewelPump
* Device: usual insulin pump


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients type 1 diabetics treated by external insulin pump; Patients with HbA1c < 8.5% Patients who signed consent Exclusion Criteria: Patients type 2 diabetics Patients who have all serious diseases that could interfere with the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: JewelPump<br>JewelPump for the first treatment period followed by the usual pump for the second treatment period | Device: JewelPump<br> <br> Device: usual insulin pump<br> <br> |
| Active Comparator: Usual insulin pump<br>Patients in the arm 2, will have the usual insulin pump for the first treatment period, followed with the second period which they will have the JewelPump. | Device: JewelPump<br> <br> Device: usual insulin pump<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time spent in glycemic area 70-180 mg / dl, measured continuously for 5 days with a continuous glucose monitoring (CGM) DEXCOM G4 | Evaluate the non-inferiority of JewelPump compared to the usual pump patient, on glycemic control. | up to 5 days of each treatment period | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time spent in the strict glycemic area 80-140 mg / dl | Evaluate the superiority of JewelPump versus usual pump; | up to 5 days of each treatment period | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Glycemic control, JewelPump accuracy